An Energy Bargain With a Covered-Call Twist
As inflation creeps back, here’s my next energy play.
Forget SpaceX, Here’s a Cheaper Way for Investors to Get Into Orbit
The best space opportunity may not be the one everyone is talking about. Here’s how to play this little-known name.
ASML’s ‘Bull Flag’ and Guidance Has My Attention: Here’s My Plan
When a ‘monopoly’ offers expansion plans like this it piques my interest.
A True Contrarian Play on an AI ‘Casualty’
Wall Street has turned negative on this software giant. Here’s why I’m willing to step in.
Biotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.
With shares pulling back after a capital raise, this strategy offers double-digit upside potential in addition to downside protection of more than 20%.
Covered Call ETFs: Smart Income Tool or Overpriced Compromise?
Losing money hurts more than winning feels good, and covered call ETFs are built entirely around that fear. But is the peace of mind they buy worth the price?
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
Wendy’s Goes Full Meme: How I’m Riding the Reddit Momentum
This is nothing more than a trading vehicle, but a double stack of Wall Street Bets and 38% short interest makes it appetizing.
Options Trading: Taking a Shot on Celestica After Last Week’s Hit
The stock has come down sharply from the highs and looks poised for a strong bounce.
While Everyone Was Selling, I Initiated a New Position in This Mid-Cap Biotech
I made exactly one trade Friday — and I went to Denmark to do it.